Adrien C.
- Country
- France
- Department
- Service d'hématologie clinique
Research Overview
- Efficacy of Venetoclax Plus Cytarabine Versus Idarubicin Plus Cytarabine in Post-Remission Therapy for Elderly Patients with Acute Myeloid Leukemia
- Phase I/II Open-Label Study of Azacitidine and Venetoclax in Untreated Higher-Risk Myelodysplastic Syndromes Ineligible for Allogeneic Transplantation
- Phase II Evaluation of Azacitidine and Venetoclax Combination Therapy in Higher-Risk Chronic Myelomonocytic Leukemia Patients
Data & Insights
Has run more than one trial at 31 of 53 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating advanced blood disorders, with particular emphasis on myelodysplastic syndromes (MDS) across different risk categories, from lower-risk to higher-risk presentations.
- High-risk MDS treatment strategies
- Novel combination therapies
- Transplant-ineligible patient care
Their research explores innovative therapeutic combinations including ONUREG and VENETOCLAX for patients who cannot undergo allogenic transplantation.
Anemia Management
The investigator focuses on developing treatment approaches for anemia in hematological conditions, particularly studying the timing and efficacy of erythropoietin therapy in lower-risk MDS patients.
- Early intervention strategies
- Transfusion dependency prevention
- Novel anemia therapeutics
Their work includes evaluation of KER-050 for treating anemia in various risk categories of MDS.
Leukemia Treatment
The investigator conducts research in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), focusing on elderly patients and those with higher-risk disease profiles.
- Elderly-specific treatment protocols
- Post-remission therapy optimization
- Combination treatment approaches
Their research includes investigating venetoclax-based combinations with conventional therapies for various leukemia subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.